Ru-Based Photocaged Kinase Inhibitors Operative under Deep-Red Light Irradiation
Journal of the American Chemical Society · 12.08.2026 · 148 (31) · 33333-33341
DOI: 10.1021/jacs.6c07801 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Chemical Society, online erschienen am 03.08.2026. Verfasst von Pragti und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Cincinnati, Cincinnati, Ohio45221, United States. Hauptthemen laut MEDLINE: Ruthenium, Protein Kinase Inhibitors, Imatinib Mesylate, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Science Foundation (NSF), Ohio Supercomputer Center.
Abstract (Originalsprache)
Light-activated control over drug activity offers a powerful strategy to improve therapeutic selectivity, yet most photoresponsive systems rely on ultraviolet or short-wavelength visible light with limited tissue penetration. Here we report two ruthenium(II) polypyridyl complexes bearing extended donor−π–acceptor ligands and a photocaged kinase inhibitor, imatinib, that enable efficient drug release under deep-red light (660 nm) irradiation. Systematic photophysical and photochemical studies demonstrate that π-conjugation engineering red-shifts metal-to-ligand charge-transfer absorption while preserving clean photoinduced release of coordinated imatinib from the ruthenium center. In BCR–ABL–positive leukemia cells, these complexes exhibit minimal dark toxicity but pronounced light-dependent cytotoxicity, accompanied by apoptosis and suppression of oncogenic BCR–ABL phosphorylation. Effective activity in 3D tumor spheroids was also observed, confirming efficient penetration and photoactivation in a physiologically relevant model. Together, these results establish a molecular design strategy for developing deep-red-light-activated Ru(II) photocages and highlight their potential for spatiotemporally controlled kinase inhibition in cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, University of Cincinnati, Cincinnati, Ohio45221, United States.
- Department of Chemistry, University of Illinois Chicago, Chicago, Illinois60607, United States.
- Division of Pharmaceutical Science, James L.Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio45221, United States.
- Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio45267, United States.
ORCID-Profile: Bidyut Kumar Kundu, Wasim Feroz, Jiajie Diao, Yujie Sun
Förderung
- NIGMS NIH HHS
- National Science Foundation (NSF)
- Ohio Supercomputer Center
- National Institutes of Health (NIH)
Zitieren
APA
Pragti, Kundu, B. K., Feroz, W., Garrett, J., Diao, J., & Sun, Y. (2026). Ru-Based Photocaged Kinase Inhibitors Operative under Deep-Red Light Irradiation. Journal of the American Chemical Society, 148(31), 33333-33341. https://doi.org/10.1021/jacs.6c07801
Vancouver
Pragti, Kundu BK, Feroz W, Garrett J, Diao J, Sun Y. Ru-Based Photocaged Kinase Inhibitors Operative under Deep-Red Light Irradiation. Journal of the American Chemical Society. 2026;148(31):33333-33341. doi:10.1021/jacs.6c07801
BibTeX
@article{Pragti2026,
author = {Pragti and Kundu, Bidyut Kumar and Feroz, Wasim and Garrett, Joan and Diao, Jiajie and Sun, Yujie},
title = {Ru-Based Photocaged Kinase Inhibitors Operative under Deep-Red Light Irradiation},
journal = {Journal of the American Chemical Society},
year = {2026},
volume = {148},
number = {31},
pages = {33333--33341},
doi = {10.1021/jacs.6c07801}
}
EUVIMED